Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide

Brain Research Bulletin

Volumn 64, Issue 4, 2004, Pages 339-345

  Burger, Marilise ^a   Fachinetto, Roselei ^b   Calegari, Luciano ^a   Paixão, Márcio W ^b   Braga, Antônio L ^b   Rocha, João B T ^b  

^a Departamento de Fisiologia

^b Centro de Ciências Naturais e Exatas   (Brazil)

Author keywords

Antioxidant; Diphenyl diselenide; Orofacial dyskinesia; Reserpine; TBARS

Indexed keywords

DIPHENYL DISELENIDE; ORGANOSELENIUM DERIVATIVE; RESERPINE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; UNCLASSIFIED DRUG;

AGING; ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DYSKINESIA; MALE; MASTICATION; MUSCLE TWITCH; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OROFACIAL DYSKINESIA; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

EID: 84984534297     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2004.09.006     Document Type: Article

References (70)

1. V.C. Abilio, J.A.R. Vera, L.S.M. Ferreira, C.R.M. Duarte, R.C. Carvalho, C.C. Grassl, C.R. Martins, D. Torres-Leite, M. Bignotto, S. Tufik, R.A. Ribeiro, and R. Frussa-Filho Effects of melatonin on orofacial movements in rats Psychopharmacology 161 2002 340 347
2. V.C. Abilio, C.C. Araujo, M. Bergamo, P.R. Calvente, V. D'Almeida, A. Ribeiro Rde, and R. Frussa-Filho Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats Prog. Neuropsychopharmacol. Biol. Psychiatry 2 2003 7109 7114
3. B.N. Ames, M.K. Shigenaga, and T.M. Hagen Oxidants, antioxidants and the degenerative diseases of aging Proc. Natl. Acad. Sci. U.S.A. 90 1993 7915 7922
4. O.A. Andreassen, and H.A. Jorgensen Neurotoxicity associated with neuroleptic-induced rats, implications for tardive dyskinesia Prog. Neurobiol. 61 2000 525 531
5. O.A. Andreassen, R.J. Ferrante, T.O. Aamo, M.F. Beal, and H.A. Jorgensen Oral dyskinesias and histopatological alterations in substantia nigra after long-term haloperidol treatment of old rats Neuroscience 122 2003 717 725
6. R.J. Baldessarini, and F.I. Tarazi Drugs and the treatment of psychiatric disorders J.G. Hardman L.E. Limbird A.G. Gilman The Pharmacological Basis of Therapeutics 2001 Goodman and Gilman's New York 485 520
7. M. Bergamo, V.C. Abílio, C.M.T. Queiroz, H.N. Barbosa-Junior, L.R.A. Abdanur, and R. Frussa-Filho Effects of age on a new animal model of tardive dyskinesia Neurobiol. Aging 18 1997 623 629
8. A.L. Braga, G. Zeni, L.H. Andrade, and C.C. Silveira Stereoconservative formation and reactivity of α-chalcogen-functionalized vinylithium compounds from α-bromo-vinylic chalcogeides Synlet 5 1997 595 596
9. M.E. Burger, A. Alves, L. Callegari, F.R. Athaide, C.W. Nogueira, G. Zeni, and J.B.T. Rocha Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum Progr. Neuropharmacol. Biol. Psychiatry 27 2003 135 140
10. J.L. Cadet, and J.B. Lohr Possible involvement of free radicals in neuroleptic-induced movement disorders: evidence from treatment of tardive dyskinesia with Vitamin E Ann. N. Y. Acad. Sci. 570 1989 176 185
11. I. Cantuti-Casteveltri, Shukitt-Hale, Barbara, and J.A. Joseph Dopamine neurotoxicity: age-dependent behavioral and histological effects Neurobiol. Aging 24 2003 697 706
12. R.C. Carvalho, R.H. Silva, V.C. Abílio, P.N. Barbosa, and R. Frussa-Filho Antidyskinetic effects of risperidone on animal models of tardive dyskinesia in mice Brain Res. Bull. 60 2003 115 124
13. D.E. Casey Tardive dyskinesia-pathophysiology F.E. Bloom D.J. Kupfer Pyschopharmacology: The Fourth Generation of Progress 1995 Raven Press Ltd. New York 1497 1502
14. D.E. Casey Tardive dyskinesia: pathophysiology and animal models J. Clin. Psych. 61 2000 5 9
15. D.E. Casey Tardive dyskinesia reversible and irreversible D.E. Casey T.N. Chase A.V. Christensen J. Gerlach Dyskinesia: Research and Treatment 1985 Springer-Verlag Berlin 88 98
16. J.T. Coyle, and P. Puttfarcken Oxidative stress, glutamate and neurodegenerative disorders Science 262 1993 689 695
17. P.N. Dannon, E. Lepkifker, I. Iancu, R. Ziv, N. Horesh, and M. Kotler Vitamin E treatment in tardive dyskinesia Hum. Psychopharmacol. 12 1997 217 220
18. R.C. Dutra, A.P. Andreazza, S.T. Andreatini, and M.A.B.F. Vital Behavioral effects of MK-801 on reserpine-treated mice Prog. Neuro-Psychopharmacol. Biol. Psych. 26 2002 487 495
19. M.E. Egan, J. Apud, and R.J. Wyatt Treatment of tardive dyskinesia Schiz. Bull. 23 1997 583 609
20. H.C. Fibiger, and K.G. Ljoyd Neurobiological substrates of tardive dyskinesia: the GABA hypothesis Trends Neurosci. 7 1984 462 464
21. R.A. Floyd Antioxidants, oxidative stress, and degenerative neurological disorders Proc. Soc. Exp. Biol. Med. 222 1999 236 245
22. G. Ghisleni, L. Porciúncula, H. Cimarosti, J.B.T. Rocha, C.S. Salbego, and D.O. Souza Diphenil diselenide protects rat hippocampal slices submitted to oxygen-glucose deprivation and diminishes inducible nitric oxide synthase immunocontent Brain Res. 986 2003 196 199
23. L.M. Gunne, U. Andersson, U. Bondesson, and P. Johansson Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration Pharmacol. Biochem. Behav. 25 1986 897 901
24. D. Harman Role of free radicals in aging and disease Ann. N. Y. Acad. Sci. 673 1992 126 141
25. B.H. Harvey, and A. Nel Role of aging and striatal nitric oxide synthase activity in na animal model of tardive dyskinesia Brain Res. Bull. 61 2003 407 416
26. K. Hensley, and R.A. Floyd Reactive oxygen species and protein oxidation in aging: a look back, a look ahead Arch. Biochem. Biophys. 397 2002 377 383
27. H. Imai, H. Masayasu, D. Dewar, D.I. Graham, and I.M. Macrae Ebselen protects both gray model of focal and white matter in a rodent cerebral ischemia Stroke 32 2001 2149 2156
28. P. Johansson, D.E. Casey, and L.M. Gunne Dose-dependent increases in rat spontaneous chewing rats during long-term administration of haloperidol but not clozapine Psychopharmacol. Bull. 22 1986 1017 1019
29. J.M. Kane, M. Woerner, and J.A. Lieberman Tardive dyskinesia: prevalence, incidence and risk factors J. Clin. Psychopharmacol. 8 Suppl. 4 1988 52 56
30. L.O. Klotz, and H. Sies Defenses against peroxynitrite: selenocompounds and flavonoids Toxicol. Lett. 14 141 2003 125 132
31. S.K. Kulkarni, and P.S. Naidu Tardive dyskinesia: an update Drugs Today 37 2001 97 119
32. J.B. Lohr Oxygen free radicals and neuropsychiatric illness Arch. Gen. Psychiatry 48 1991 1097 1106
33. J.B. Lohr, and D.V. Jeste Neuroleptic-induced movement disorders: tardive dyskinesia and other tardive syndromes J.O. Cavenar Jr. Psichiatry 1988 Lippincott Philadelphia, PA 1 17
34. J.B. Lohr, R. Kuczenski, and A.B. Niculescu Oxidative mechanisms and tardive dyskinesia CNS Drugs 17 2003 47 62
35. M.J. Marino, and P.J. Conn Direct and indirect modulation of the N-methil-d-aspartate receptor: potential for the development of novel antipsychotic therapies Curr. Drug Target 1 2002 1 16
36. F.C. Meotti, V.C. Borges, G. Zeni, J.B.T. Rocha, and C.W. Nogueira Potential renal and hepatic toxicity of diphenyl diselenide, diphenyl ditelluride and ebselen for rats and mice Toxicol. Lett. 143 2003 9 16
37. S. Moussaoui, M. Obinu, N. Daniel, M. Reibaud, V. Blanchard, and A. Imperato The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease Exp. Neurol. 166 2000 235 245
38. G. Mugesh, W.W. du Mont, and H. Sies Chemistry of biologically important synthetic organoselenium compounds Chem. Ver. 1001 2001 2125 2179
39. A. Müller, H. Gabriel, and H. Sies A novel biologically active selenoorganic compound protective glutathione-dependent effect of PZ 51 (Ebselen) against ADP-Fe-induced lipid peroxidation in isolated hepatocytes Biochem. Pharmacol. 34 1985 1185 1189
40. P.S. Naidu, A. Singh, and S.K. Kulkarni Effect of Withania somnifera root extract on haloperidol-induced orofacial dyskinesia: possible mechanisms of action J. Med. Food 2003 107 114
41. P.S. Naidu, A. Singh, and S.K. Kulkarni Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin Pharmacology 70 2004 59 67
42. S. Namura, I. Nagata, S. Takami, H. Masayasu, and H. Kikuchi Ebselen reduces cytochrome c release from mitochondria and subsequent DNA fragmentation after transient focal cerebral ischemia in mice Stroke 32 2001 1906 1911
43. J.L. Neiswander, E. Castañeda, and D.A. Davis Dose-dependent differences in the development of reserpine-induced oral-dyskinesia in rats: support for a model of tardive dyskinesia Psychopharmacology 116 1994 79 84
44. C.W. Nogueira, F.C. Meotti, E. Curte, C. Pilissão, G. Zeni, and J.B.T. Rocha Investigations into the potential neurotoxicity induced by diselenides in mice and rats Toxicology 183 2003 29
45. C.W. Nogueira, E.B. Quinhones, E.A.C. Jung, G. Zeni, and J.B.T. Rocha Anti-inflamatory and antinociceptive activity of diphenyl diselenide Inflamm. Res. 52 2003 56 63
46. C.W. Nogueira, L.N. Rotta, G. Zeni, D.O. Souza, and J.B.T. Rocha Exposure to ebselen changes glutamate uptake and release by rat brain synaptosomes Neurochem. Res. 27 3 2002 283 288
47. H. Ohkawa, H. Ohishi, and K. Yagi Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
48. L.O. Porciúncula, J.B.T. Rocha, C.R. Boeck, D. Vendite, and D.O. Souza Ebselen prevents excitotoxicity provoked by glutamate in rat cerebellar granule neurons Neurosci. Lett. 299 2001 217 220
49. C.M.T. Queiróz, R.D. Piovezan, and R. Frussa-Filho Reserpine does not induce orofacial dyskinesia in spontaneously hypertensive rats Eur. J. Pharmacol. 356 1998 105 108
50. V. Raghavendra, P.S. Naidu, and S.K. Kulkarni Reversal of reserpine-induced vacuous chewing movements in rats by melatonin: involvement of peripheral benzodiazepine receptors Brain Res. 904 2001 149 152
51. M.P. Rayman The importance of selenium to human health Lancet 356 2000 233 241
52. J.I. Rossato, L.A. Ketzer, F.B. Centurião, S.J.N. Silva, D.S. Lûdtke, G. Zeni, A.L. Braga, M.A. Rubin, and J.B.T. Rocha Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain Neurochem. Res. 27 2002 297 303
53. J.I. Rossato, G. Zeni, C.F. Mello, M.E. Rubin, and J.B.T. Rocha Ebselen blocks the quinolinic acid-induced production of thiobarbituric acid reactive species but does not prevent the behavioral alterations produced by intra-striatal quinolinic-acid administration in the rat Neurosci. Lett. 318 2002 137 140
54. N.M.J. Rupniak, S. Mann, M.D. Hall, S. Fleminger, G. Kilpatrick, P. Jenner, and C.D. Marsden Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat Psychopharmacology (Berlin) 84 1984 503 511
55. P.S. Sachdev The current status of tardive dyskinesia Aust. N. Z. J. Psych. 34 2000 355 369
56. P. Sachdev, T. Saharov, and S. Cathcart The preventative role of antioxidant (selegiline and Vitamin E) in a rat model of tardive dyskinesia Biol. Psychiatry 46 1999 1672 1681
57. R.E. See, and M.A. Chapman Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats Eur. J. Pharmacol. 263 1994 269 276
58. S. Siegel Nonparametric Statistic for the Behavioral Sciences 1956 McGraw-Hill New York pp. 117-127
59. R.E. Steinpreis, and J.D. Salamone Effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats Pharmacol. Biochem. Behav. 46 1993 405 409
60. A.N. Sussman, Tran-Nguyen, T.L. Ly, and J.L. Neisewander Acute reserpine administration elicits long-term spontaneous oral dyskinesia Eur. J. Pharmacol. 337 1997 157 160
61. G.C. Tsai, D.C. Golf, R.W. Chang, J. Flood, L. Baer, and J.T. Coyle Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia Am. J. Psych. 155 1998 1207 1213
62. M.A.B.F. Vital, R. Frussa-Filho, and J. Palermo-Neto Effects of monosialoganglioside on new model of tardive dyskinesia Prog. Neuro-Psychopharmacol. Biol. Psychiatry 21 1997 1169 1179
63. J.L. Waddington Spontaneous orofacial movements induced by very long-term neuroleptic drug administration: phenonomenology, pathophysiology and putative relationship to tardive dyskinesia Psychopharmacology 101 1990 431 447
64. J.L. Waddington, A.G. Molloy, and K.M. O'Boyle Behavioral effects of long-term treatment with further typical neuroleptics and selective D2 dopamine receptor antagonists in young vs. aged animals M. Sndier A. Dahistron R. Belmaker Progress in Catecholamine Research. Part B. Central Aspects 1988 Liss New York 43 46
65. J.L. Waddington, H.A. Youssef, A.G. Molloy, K.M. O'Boyle, and M.T. Pugh Association of intellectual impairment, negative symptoms and aging with abnormal, involuntary movements (tardive dyskinesia) in schizophrenia: clinical and animal studies J. Clin. Psychiatry 46 1985 29 33
66. A. Wendel, H. Fausel, and R. Otter A novel biologically active seleno-organic compound-II Activity of PZ 51 in relation to glutathione peroxidase Biochem. Pharmacol. 33 1984 3241 3245
67. A.P. Wickens Ageind and free radical theory Respir. Physiol. 128 2001 379 391
68. S.R. Wilson, P.A. Zucker, R.-R.C. Huang, and A. Spector A development of synthetic compounds with glutathione peroxidase activity J. Am. Chem. Soc. 111 1989 5936 5939
69. M.G. Woerner, J.M. Alvir, B.I. Salz, J.A. Lieberman, and J.M. Kane Prospective study of tardive dyskinesia in the elderly: rates and risk factors Am. J. Psyquiatry 155 1998 1521 1528
70. H. Yokoyama, N. Kasai, Y. Ueda, R. Niwa, R. Konaka, N. Mori, N. Tsuchihashi, T. Matsue, H. Ohya-Nishiguchi, and H. Kamada In vivo analysis of hydrogen peroxide and lipid radicals in the striatum of rats under long-term administration of a neuroleptic Free Radic. Biol. Med. 24 1998 1056 1060